Boron Neutron Capture Therapy: Next-generation Radiation Therapy That Generates α-Rays inside Cancer Cell

DOI Web Site Web Site 15 References
  • Nakamura Hiroyuki
    Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology

Bibliographic Information

Other Title
  • ホウ素中性子捕捉療法：がん細胞内でα線を発生させる次世代放射線治療
  • ホウソ チュウセイシ ホソク リョウホウ : ガン サイボウ ナイ デ αセン オ ハッセイ サセル ジセダイ ホウシャセン チリョウ

Search this article

Abstract

Boron neutron capture therapy（BNCT） has been attracting growing interest as one of the minimally invasive cancer therapies. BNCT uses the nuclear reaction between low-energy thermal neutron（0.025eV） and boron-10（10B）, and the generated α-particle and lithium nuclei are high linear energy transfer particles（2.4MeV） that are sufficiently powerful to kill cells. Therefore, selective delivery of 10B atoms to tumor is essential for effective BNCT. Mercaptoundecahydrododecaborate（Na2［B12H11SH］） and p-boronophenylalanine（BPA） have been used in BNCT for many years. BPA, in particular, has been widely used for the treatment of not only melanoma but also brain tumor and head and neck cancer. In Japan, which succeeded in developing a small accelerator for BNCT ahead of the world, the phase II clinical study of BPA-BNCT for brain tumor and head and neck cancer patients has been completed and their applications for medical approval have been filed. However, development of new boron carriers is still strong requirements for patients who are not able to be treated with BPA. In this review, recent development of DDS-based new boron carriers is summarized.

Journal

  • Drug Delivery System

    Drug Delivery System 35 (2), 129-136, 2020-03-25

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(15)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top